Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations

Speciality: Oncology

Description:

Welcome to this insightful video featuring Dr. Viraj Nevrekar, where he delves into the molecular differences between two critical EGFR mutations—Exon 19 deletion and Exon 21 L858R. These mutations are pivotal in non-small cell lung cancer (NSCLC) and influence treatment responses, making their understanding essential for clinicians and researchers. Dr. Nevrekar expertly breaks down the structural and functional disparities between these mutations, explaining how Exon 19 deletions lead to ligand-independent activation of EGFR, while L858R alters the kinase domain’s affinity for ATP. His analysis provides a clear perspective on why these differences matter in therapeutic decision-making. 

In the second segment, Dr. Nevrekar explores the clinical implications of these EGFR mutations, highlighting how Exon 19 deletions often correlate with better responses to tyrosine kinase inhibitors (TKIs) compared to L858R. He discusses recent studies that reveal differences in downstream signaling pathways, tumor microenvironments, and resistance mechanisms between the two variants. By presenting real-world data and case studies, he underscores the importance of personalized medicine in NSCLC, ensuring viewers grasp the practical relevance of these molecular distinctions in improving patient outcomes. 

As the discussion concludes, Dr. Nevrekar emphasizes the ongoing research into novel therapeutic strategies targeting these mutations, including next-generation TKIs and combination therapies. His engaging presentation not only educates but also inspires further exploration into precision oncology. Don’t miss this comprehensive breakdown—watch the full video to gain valuable insights and stay tuned for more enlightening discussions from Dr. Nevrekar on emerging trends in molecular oncology!
 

See More Webinars @ Hidoc Webinars